| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11611 | KBP-7018 | A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively. |
|
| DC11751 | UHC1 | A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism. |
|
| DC11750 | SR-1664 Featured | SR-1664 is a novel potent, non-agonist PPARγ ligand that blocks the Cdk5-mediated phosphorylation in vitro (IC50=80 nM) and in vivo, without the classical agonism. |
|
| DC11968 | OSU-03013 | A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM. |
|
| DC24024 | Z-360 | A novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM. |
|
| DC11607 | JTZ-951(Enarodustat) Featured | A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC11608 | JTZ-951 hydrochloride | A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2. |
|
| DC11546 | Azeloprazole sodium | A novel potent, orally active proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM. |
|
| DC21707 | STX-681 | A novel potent, orally active, dual-acting aromatase and steroid sulfatase (STS) inhibitor with ICI0 of 0.82 nM and 39 nM, respectively. |
|
| DC11599 | PF-739 | A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers. |
|
| DC20806 | BMS-852927 | A novel potent, partial LXRβ-selective agonist (EC50=9 nM) with 20% LXRα and 88% LXRβ activity compared to a full pan agonist in transactivation assays. |
|
| DC11610 | AKS1-IN-19 | A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3. |
|
| DC22745 | SLx-4090 Featured | A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM. |
|
| DC11696 | CM-579 | A novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 16 nM and 32 nM for G9a and DNMT1, respectively. |
|
| DC21667 | SMM-295 | A novel potent, selective cannabinoid receptor 2 (CB2) agonist with Ki of 12 nM, >30-fold selectivity over CB1. |
|
| DC20841 | BRD6989 Featured | A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex. |
|
| DC11953 | MU 380 | A novel potent, selective CHK1 inhibitor 2 nM, >80-fold selectivity over CHK2. |
|
| DC11982 | CX815 | A novel potent, selective CXCR2 inhibitor with IC50 of 0.4 nM. |
|
| DC11981 | CX4152 | A novel potent, selective CXCR2 inhibitor with IC50 of 7.6 nM. |
|
| DC11827 | 9-ING-41 Featured | 9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2]. |
|
| DC11904 | Olinciguat (IW-1701) Featured | Olinciguat (IW-1701) is an oral guanylate cyclase (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay. |
|
| DC22940 | SKF-32802 | A novel potent, selective hERG potassium channel (Kv11.1) activator that induces a leftward shift in the voltage dependence of activation.. |
|
| DC11854 | IDX899 | A novel potent, selective HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with EC50 of 1, 1.3, 2.8 and 11 nM for WT, K103N, Y181C and K103N/Y181C, respectively. |
|
| DC21703 | STAT5 inhibitor 17f Featured | A novel potent, selective inhibitor of phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation. |
|
| DC11497 | IRAK4-IN-28 | A novel potent, selective IRAK4 inhibitor with IC50 of 51 nM. |
|
| DC22938 | ICA-027243 Featured | A novel potent, selective KCNQ2/Q3 (Kv7.2/Kv7.3) potassium channel opener/activator with EC50 of 0.38 uM.. |
|
| DC22741 | RY796 R-form | A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC22744 | RY796 racemate | A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC12019 | RY796 | A novel potent, selective Kv2 channel inhibitor that potently inhibits Kv2.1 and Kv2.2 with IC50 of 0.14 and 0.09 uM, respectively. |
|
| DC11613 | Mcl1-IN-26 | A novel potent, selective Mcl-1 inhibitor with IC50 of <3 nM in FRET assays. |
|
